10:34 AM EST - Zymeworks Inc. : Announced today that the abstract highlighting new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for an oral presentation at the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1 through 5. Zymeworks Inc.
shares T.ZYME are trading up $0.22 at $16.08.
